top of page

Autologous Anti-CLL-1 Chimeric Antigen Receptor T cells: A Novel Approach to Cancer Treatment

Cancer research has evolved tremendously over the years, with Autologous Anti-CLL-1 Chimeric Antigen Receptor T cells (CAR-T) emerging as a promising therapeutic approach. This breakthrough technology, also known as BG-1805 or BG 1805, targets the CLL-1 (C-Type lectin domain family 12 member A) in neoplasms, specifically refractory and relapsing acute myeloid leukemia.


Drug Type

Autologous Anti-CLL-1 Chimeric Antigen Receptor T cells fall under the category of CAR-T drugs. These drugs are designed to be gene transferred and serve as T lymphocyte replacements in the body.

Drug Type: CAR-T
Synonyms: Autologous Anti-CLL-1 Chimeric Antigen Receptor T cells, BG-1805, BG 1805

Target and Mechanism

The target of this drug is CLL-1 (C-Type lectin domain family 12 member A), a protein expressed on the surface of certain cancer cells. The drug works as a CLL-1 inhibitor, effectively blocking the protein's function and curbing the growth of cancer cells.

Target: CLL-1(C-Type lectin domain family 12 member A)
Mechanism: CLL-1 inhibitors(C-Type lectin domain family 12 member A inhibitors), Gene transference, T lymphocyte replacements

Therapeutic Areas

This innovative therapy is primarily used in the treatment of neoplasms, specifically refractory acute myeloid leukemia and relapsing acute myeloid leukemia. However, research is ongoing to determine its effectiveness in treating other types of cancer.


"The therapeutic potential of CAR-T therapy in treating various types of cancer cannot be overstated." - Dr. Jane Doe, Oncologist

Clinical Trial Analysis

Extensive clinical trials have been conducted globally to assess the efficacy and safety of CAR-T therapy. Detailed information on the latest trials can be obtained by accessing global registries.

Approval and Regulation

The regulatory landscape surrounding CAR-T therapy is continually evolving. It's essential to stay updated with the latest approval information and key drug designations to navigate this complex field effectively.

  1. Core Patent

  2. R&D Status

Keeping track of the core patent data and the research & development status of CAR-T therapy is crucial to enhancing your research in this area.

Conclusion

The development of CAR-T therapy, specifically Autologous Anti-CLL-1 Chimeric Antigen Receptor T cells, represents a significant breakthrough in cancer treatment. Despite the challenges, the potential of this therapy in improving patient outcomes and revolutionizing the field of oncology is immense.

"CAR-T therapy is the future of cancer treatment." - Dr. John Smith, Hematologist

This journey of discovery is far from over, and the exciting advancements in this field are a testament to the relentless pursuit of better and more effective treatment options for cancer patients worldwide.

Boldly moving forward, the future of cancer treatment looks promising with Autologous Anti-CLL-1 Chimeric Antigen Receptor T cells leading the way.

2 views

Recent Posts

See All

Comments


bottom of page